169 related articles for article (PubMed ID: 29512183)
1. Persistent pruritus in psoriatic patients during administration of biologics.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Ishida-Yamamoto A
J Dermatol; 2018 Aug; 45(8):e223. PubMed ID: 29512183
[No Abstract] [Full Text] [Related]
2. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Nast A; Spuls PI; van der Kraaij G; Gisondi P; Paul C; Ormerod AD; Saiag P; Smith CH; Dauden E; de Jong EM; Feist E; Jobling R; Maccarone M; Mrowietz U; Papp KA; Reich K; Rosumeck S; Talme T; Thio HB; van de Kerkhof P; Werner RN; Dressler C
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1951-1963. PubMed ID: 28895202
[No Abstract] [Full Text] [Related]
3. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.
Dressler C; Rosumeck S; Werner RN; van der Kraaij G; van Lumig P; Wakkee M; Spuls P; Nast A
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):1964-1977. PubMed ID: 28944515
[No Abstract] [Full Text] [Related]
4. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
Oiwa T; Honda T; Otsuka A; Kabashima K
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
[No Abstract] [Full Text] [Related]
5. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
[TBL] [Abstract][Full Text] [Related]
6. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Systemic Treatments of Psoriasis on Pruritus: A Systemic Literature Review and Meta-Analysis.
Théréné C; Brenaut E; Barnetche T; Misery L
J Invest Dermatol; 2018 Jan; 138(1):38-45. PubMed ID: 28887107
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of apremilast and biologics in patients with psoriasis showing biologic fatigue.
Takamura S; Sugai S; Taguchi R; Teraki Y
J Dermatol; 2020 Mar; 47(3):290-294. PubMed ID: 31867729
[TBL] [Abstract][Full Text] [Related]
9. Treating psoriasis: patient assessment, treatment goals, and treatment options.
Pariser DM; Kircik LH; Stein Gold LF
Cutis; 2019 Apr; 103(4S):S4-S7. PubMed ID: 31116804
[TBL] [Abstract][Full Text] [Related]
10. Serum fatty acid-binding protein 4 level is inversely correlated with serum thymus and activation-regulated chemokine level in psoriatic patients achieving clear skin by biologics.
Honma M; Shibuya T; Iinuma S; Ishida-Yamamoto A
J Dermatol; 2019 Apr; 46(4):e116-e117. PubMed ID: 30216494
[No Abstract] [Full Text] [Related]
11. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
12. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
[No Abstract] [Full Text] [Related]
13. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald JM; Klufas DM; Strober BE
J Drugs Dermatol; 2015 Aug; 14(8):888-92. PubMed ID: 26267735
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
[TBL] [Abstract][Full Text] [Related]
16. Experience with biologics for psoriasis in daily practice: switching is worth a try.
Lecluse LL; de Groot M; Bos JD; Spuls PI
Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
[No Abstract] [Full Text] [Related]
17. Reduction in psoriasis related pruritus during biologic therapy.
Lazzeri L; Pescitelli L; Tripo L; Ricceri F; Prignano F
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 27891730
[No Abstract] [Full Text] [Related]
18. Current and Emerging Therapies for Itch Management in Psoriasis.
Stull C; Grossman S; Yosipovitch G
Am J Clin Dermatol; 2016 Dec; 17(6):617-624. PubMed ID: 27460912
[TBL] [Abstract][Full Text] [Related]
19. Psoriasis and chronic myeloid leukemia: treatment with Apremilast.
Vico-Alonso C; Sánchez-Velázquez A; Pinilla-Martin B; Andrés-Lencina JJ; Aragón-Miguel R; Calleja-Algarra A; Rivera-Díaz R
Int J Dermatol; 2020 Apr; 59(4):e102-e103. PubMed ID: 31347142
[No Abstract] [Full Text] [Related]
20. New Therapies for Psoriasis.
Leonardi CL
Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S71-3. PubMed ID: 27525355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
